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Abstract
Background—Little is known about population-based maternal, child, and system 
characteristics associated with high hospital resource use for children with orofacial clefts (OFC) 
in the US.
Methods—This was a statewide, population-based, retrospective observational study of children 
with OFC born between 1998 and 2006, identified by the Florida Birth Defects Registry whose 
records were linked with longitudinal hospital discharge records. We stratified the descriptive 
results by cleft type [cleft lip with cleft palate (CLP), cleft lip (CL) and cleft palate (CP)] and by 
isolated vs. non-isolated OFC (accompanied by other coded major birth defects). We used Poisson 
regression to analyze associations between selected characteristics and high hospital resource use 
(≥90th percentile of estimated hospitalized days and inpatient costs) for birth, post-birth, and total 
hospitalizations initiated before age two years.
Results—Our analysis included 2,129 children with OFC. Infants who were born low birth 
weight (<2500 grams) were significantly more likely to have high birth hospitalization costs for 
CLP [adjusted prevalence ratio (aPR): 1.6 (95% confidence interval (CI): 1.0–2.7)], CL [aPR: 3.0 
(95% CI: 1.1–8.1)], and CP [aPR: 2.3 (95% CI: 1.3–4.0)]. Presence of multiple birth defects was 
significantly associated with a three- to eleven-fold and a three- to nine-fold increase in the 
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prevalence of high costs and number of hospitalized days, respectively; at birth, post-birth before 
age two years and overall hospitalizations.
Conclusion—Children with CP had the greatest hospital resources use. Additionally, the 
presence of multiple birth defects contributed to greater inpatient days and costs for children with 
OFC.
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INTRODUCTION
Orofacial clefts (OFC) include cleft lip with cleft palate (CLP), cleft lip (CL), and cleft 
palate (CP). In the United States, the estimated prevalence is 5.6 per 10,000 live births for 
cleft lip with cleft palate, 5.9 per 10,000 live births for cleft palate, and 3.1 per 10,000 live 
births for cleft lip (Mai et al., 2014). OFC are among the most common birth defects and are 
an important public health concern (Mai et al., 2014; Parker et al., 2010; Yazdy et al., 2007).
OFC can impair the development of speech, hearing, language, and psychomotor and 
cognitive skills, which can create physical and emotional stress for children and their 
families and can result in substantial medical costs. OFC are surgically correctable, often 
requiring multiple procedures. Although the timing of repair may vary by institutional 
protocol or by clinical circumstances, guidelines recommend that primary surgical closure of 
the cleft lip and cleft palate should occur within the first 12 and 18 months of life, 
respectively (American Cleft Palate-Craniofacial Association, 2009). Consequently, most 
hospitalizations and costs for infants with OFC are associated with surgical repairs (Abbott 
et al., 2011; Abbott and Meara, 2011). In addition, other costs are related to non-operative 
clinical services (e.g., speech, audiological, dental/orthodontic, and psychosocial services), 
special education, early intervention, loss of parental time from work, and travel.
Several recent studies have examined mean or median health service use and expenditures 
among children with OFC in the United States (Basseri et al., 2011; Boulet et al., 2009; 
Cassell et al., 2008; Centers for Disease Control and Prevention, 2007; Deleyiannis et al., 
2013; Nguyen et al., 2013; Russo and Elixhauser, 2007; Weiss et al., 2009). Of these eight 
recent studies reporting health care costs or expenditures for children with different types of 
OFC in the United States, four used data from the Agency for Healthcare Research and 
Quality (AHRQ) Healthcare Cost and Utilization Project (HCUP) (Basseri et al., 2011; 
Centers for Disease Control and Prevention, 2007; Nguyen et al., 2014; Russo and 
Elixhauser, 2007); one used MarketScan® Commercial Claims and Encounters databases 
(Boulet et al., 2009); one used data from one U.S. hospital (Deleyiannis et al., 2013); and 
two used statewide, population-based birth defects registry data (Cassell et al., 2008; Weiss 
et al., 2009). It is difficult to compare the findings of these studies due to the different 
methods employed and variation in the cleft phenotype classifications.
Although these studies provide valuable information on average medical costs for children 
with OFC, little is known about the associations of payer status and other factors with high 
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hospital resource use for children with OFC. The purpose of this study was to examine 
factors associated with high hospital resource use (defined as ≥90th percentile of estimated 
hospitalized days and inpatient costs) for children aged 0–2 with OFC, stratified by cleft 
type and presence of other major birth defects, using a statewide, population-based birth 
defects registry.
METHODS
Study population
This study was a retrospective, observational study of children with OFC born between 
January 1, 1998, and December 31, 2006, identified by the Florida Birth Defects Registry 
(FBDR) whose records were linked with longitudinal hospital discharge data through 
December 31, 2008. The FBDR is a passive, statewide, population-based surveillance 
system that identifies infants with birth defects during the first year of life using multiple 
databases, including hospital discharge records from Florida’s Agency for Health Care 
Administration (AHCA) (Salemi et al., 2010; Salemi et al., 2011). The study population 
included children with an International Classification of Disease, 9th revision; Clinical 
Modification (ICD-9-CM) code in the FBDR for OFC (749.00–749.25) whose mothers were 
residents of Florida at the time of delivery and who had at least one inpatient discharge 
record on file during the study period, 1998–2008. Adopted children, prospective adoptees, 
and children whose mothers delivered out-of-state were excluded (Salemi et al., 2010; 
Salemi et al., 2011). In addition, children without an AHCA birth hospitalization were 
excluded from the study population in the present analysis.
Longitudinal data linkage
Historically, only hospital discharge records for the first year of life were available through 
the linkage between the FBDR and AHCA for children identified as having at least one 
FBDR-eligible ICD-9-CM code (Salemi et al., 2010; Salemi et al., 2011; Salemi et al., 
2012). More recently, a subset of FBDR children with specific birth defects, including OFC, 
were linked to AHCA discharge records beyond the first year of life as part of a 
collaborative project between the University of North Carolina at Charlotte, University of 
South Florida, Florida Department of Health FBDR, and the Centers for Disease Control and 
Prevention’s (CDC) National Center on Birth Defects and Developmental Disabilities.
For this study, the data included live births from January 1, 1998, to December 31, 2006, to 
allow for two full years of hospital discharge data for the last birth cohort. A stepwise 
deterministic strategy was used to link birth certificate records to hospital inpatient, 
ambulatory, and emergency department database, using the child’s social security number 
(SSN), maternal SSN, child’s date of birth, and child’s sex (Salemi et al., 2013). The linkage 
was done in four stages: 1) linked infant birth and maternal delivery hospital inpatient 
records together to create a maternal-infant dyad; 2) linked maternal-infant dyads from stage 
1 to infant birth certificate records; 3) linked infant birth hospital discharge inpatient records 
directly to birth certificate records for infants where maternal-infant dyads were not 
available; 4) combined valid links from stages 2 and 3 that created the base dataset for a 
given birth cohort. The linking stages were constructed hierarchically; exact matches had the 
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highest confidence, and inexact matches had lower confidence. When a link was established 
during a given stage, the record was removed from the pool of available records to be linked 
during subsequent, lower-confidence stages. Linkages were conducted separately for 
singleton and multiple births due to the increased complexity of linking records for multiple 
births (Salemi et al., 2013).
Hospitalizations and costs
The number of hospitalized days and estimated hospital costs were analyzed based on 
hospitalizations initiated, but not necessarily completed, before age two or within the first 
two years of life. This time period was chosen because primary operative correction of cleft 
lip and/or cleft palate is typically completed by that age (American Cleft Palate-Craniofacial 
Association, 2009). Number of hospitalized days and hospital costs were assessed for birth, 
post-birth, and total hospitalizations before age two. Multiple admission records were 
merged in the event of hospital transfers (Colvin et al., 2009). Transfers were defined as 
inpatient admissions that occurred on the same day that the child was discharged from a 
previous hospitalization or admissions within one day of a previous discharge with an 
accompanying “transfer” code.
Year-specific statewide cost-to-charge ratios were used for conversion of inpatient charges 
to estimated costs. According to AHRQ’s State Inpatient Database, the average all-payer 
inpatient hospital cost-to-charge ratio in Florida ranged from 0.355 in 2001 (209 hospitals 
reporting) to 0.294 in 2008 (217 hospitals reporting) (Agency for Healthcare Research and 
Quality, 2013). The cost-to-charge ratio for 2001 (0.355) was used to convert inpatient 
charges to estimated costs for the years 1998–2001 because 2001 was the earliest year 
available. Hospital costs from different years were converted to 2012 equivalent costs in 
U.S. dollars using the Producer Price Index for hospital services (U.S. Bureau of Labor 
Statistics, 2013).
Case classification
Children with OFC were classified into three mutually exclusive groups based on the ICD-9-
CM code used for their principal diagnosis. The three types of OFC included in this study 
were: “cleft of secondary hard and/or soft palate” (CP) for ICD-9-CM code 749.0; “cleft lip 
with/without cleft alveolus” (CL) for code 749.1; and “cleft lip with cleft secondary hard 
and/or soft palate” (CLP) for code 749.2. Cleft uvula (code 749.02) was excluded from 
consideration due to variability in ascertainment, diagnosis, and coding. If ICD-9-CM codes 
for both CL and CP were present, the child was classified as having CLP. When multiple 
birth defects codes were present, a clinician reviewed the ICD-9-CM codes and made case-
specific decisions regarding classification (e.g., children with OFC and a code for “other 
anomalies of nose” [ICD-9-CM code 748.1] were classified as isolated OFC) (Rasmussen et 
al., 2003).
Although recent recommendations propose classifying OFC as syndromic/non-syndromic 
rather than isolated/non-isolated, in a passive, ICD-9-CM code-based surveillance system, 
the isolated/non-isolated OFC classification is more practical and realistic (Watkins et al., 
2014). Isolated OFC was defined as having no other ICD-9-CM code for any major birth 
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defect but minor defects could be present. Non-isolated OFC was defined as the presence of 
any other ICD-9-CM code for a major, unrelated birth defect in addition to OFC. 
Additionally, presence of an ICD-9-CM code for a single gene or chromosomal syndrome 
would lead to a non-isolated classification (Rasmussen et al., 2003).
Variable construction and statistical analysis
Variables of interest included the following and are explained below: (1) selected maternal 
and child demographics; (2) Adequacy of Prenatal Care Utilization Index (APNCU) 
(Kotelchuck, 1994); (3) principal expected healthcare payer at the birth hospitalization; and 
(4) birth-hospital nursery level (I, II, or III [highest]) (American Academy of Pediatrics 
Committee on Fetus and Newborn, 2012).
1. Maternal demographics included age, race/ethnicity, nativity, parity, and education. 
Child demographics of interest included sex, preterm birth, birth weight, death, 
plurality, and presence of other major FBDR-eligible birth defects.
2. The APCNU Index is a measure of the adequacy of both initiation of and the 
receipt of prenatal care services; adequacy is classified as “inadequate,” 
“intermediate,” and “adequate/adequate plus”.
3. The child’s principal expected healthcare payer was defined as the payer recorded 
on the birth hospitalization discharge record. This was used in place of a composite 
measure of payer type based on multiple hospitalizations to avoid the reverse 
causation bias that can result if high resource use leads to subsequent change in 
payer status. Payers were categorized as private (i.e., employer-based insurance, 
including Tricare), public (i.e., Medicaid, Medicare, and other state and local 
government insurance in Florida, such as KidCare) or no insurance or self-pay/
uninsured, which was defined as no insurance or less than 30% coverage.
4. Hospital nursery level was recorded as the highest possible level in the facility (i.e., 
a hospital with Level II and III beds was classified as Level III).
All variables were stratified by isolated and non-isolated CLP, CL, and CP. Pearson chi-
square statistics were used to compare demographic characteristics of mothers and children 
with non-isolated and isolated OFC. Hospitalized days and estimated costs were presented 
as mean (with standard deviation), median (with interquartile range), and 90th percentile 
estimates for birth, post-birth, and total hospitalizations before age two years. Not all 
children had hospital discharge records available for both the birth and post-birth periods. 
Analyses for post-birth hospitalizations were restricted to children with a birth 
hospitalization who had additional admissions following the birth hospitalization; all 
children were included in the total hospitalization analyses. Wilcoxon rank-sum tests were 
used to detect differences in hospital resource utilization by phenotypic class and by isolated 
vs. non-isolated status.
High resource use was defined as the number of hospitalized days and estimated inpatient 
costs ≥90th percentile and was assessed by multivariable analysis. Given the large sample 
size, the design of our study, and the fact that our outcomes were not rare, Poisson 
regression models were constructed to produce adjusted prevalence ratios (aPR) and 95% 
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confidence intervals (CI) for each cleft type for each period of hospitalization (birth, post-
birth, and total) before age two years (Langlois et al., 2013; Zou, 2004). The results for each 
analysis were reported only for cells with at least five observations for both hospitalized 
days and cost within the relevant time period; infants who were high utilizers in one time 
period were not necessarily high utilizers in another period. We investigated statistical 
interactions for multiple combinations of variables to assess effect modification (e.g, 
prenatal care and multiple birth defects) and did not find evidence of any interaction; 
however, we had limited power to assess these interactions. The variables of interest were 
selected a priori, as described above.
All analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA). 
This study was approved by the Institutional Review Boards at the University of North 
Carolina at Charlotte, Florida Department of Health (FDOH), and CDC.
RESULTS
Of the 2,407 children with OFC born from 1998 through 2006 and identified by the FBDR, 
174 children were excluded due to lack of linked hospital discharge records or the presence 
of hospital discharge records without associated charges. Children excluded were more 
likely to be born to Hispanic mothers and foreign-born mothers and were more likely to be 
twins or higher order multiples than children included in the analysis. Children without a 
birth hospitalization record (n=102) and those with discharge records who did not have 
associated charges (n=2) were also excluded from this analysis. The number of children 
included in the study sample was 2,129, with a phenotypic distribution of 48.5% CLP 
(n=1,033), 17.3% CL (n=368), and 34.2% CP (n=728). Isolated OFC was found in 68.3% 
(n=1,455) of children (Figure 1).
The distribution of maternal age was significantly different when comparing isolated to non-
isolated CLP (p=0.02), with a larger percentage of children with isolated CLP born to 
mothers less than 25 years old (Table 1). This difference was not observed for children with 
CL or CP. Children with non-isolated CLP and CP were more likely to be born to foreign 
born mothers (p=0.0002 and p=0.009, respectively), and children with all subtypes of non-
isolated OFC were more likely to be born in facilities with a higher nursery care level (CLP: 
p=<0.0001, CL: p=0.03, and CP: p=0.0009, respectively) than their counterparts with 
isolated OFC (Table 1). More than 70% of mothers reported having received adequate/
adequate plus prenatal care for all subtypes of OFC. In addition, compared to children with 
isolated OFC, significantly higher rates of preterm birth (< 37 weeks’ gestation) and low 
birth weight (<2,500 grams) were observed for children with all subtypes of non-isolated 
OFC. Additionally, higher rates of death at birth hospitalization and before age two were 
observed in children with non-isolated CLP compared with isolated CLP as well as higher 
rates of death before age two in children with non-isolated CP or CLP compared with 
isolated CP or CLP (Table 1).
Congenital heart defects (ICD-9-CM: 745.00–747.90) were the most prevalent grouping of 
other major defects among children with non-isolated CLP (63.4%) and CL (57.8%), and the 
second most prevalent grouping of defects for children with non-isolated CP (59.0%). 
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Musculoskeletal defects (ICD-9-CM: 754.00–756.90) were the most prevalent grouping of 
defects in children with non-isolated CP (61.3%) and the second most prevalent type of 
defects in children with non-isolated CLP (37.2%) and CL (35.6%) (Table 2).
Birth hospitalizations represented 35.0% of the total 6,087 hospitalizations during the study 
period and, overall, accounted for 64.5% of all hospitalized days and 57.3% of 
hospitalization costs (data not shown). Mean and median number of hospitalized days and 
inpatient costs during the birth hospitalization were higher among children with non-isolated 
OFC than those with isolated OFC for all subtypes and were higher for children with 
isolated CLP and CP than children with isolated CL. The same trends were observed for 
post-birth hospitalizations and total hospitalizations before age two years (Table 3).
During the birth hospitalization, none of the maternal characteristics were found to be 
statistically significantly associated with high hospital resource use (Table 4). Among other 
characteristics examined, birth hospital nursery care level was associated with high resource 
use for children with CLP. Children born at hospitals with level II nurseries were less likely 
to have had high resource use than those born at hospitals with level III nurseries.
Several child characteristics were associated with resource use during the birth 
hospitalization. Females with CLP were more likely than males to have had a high number 
of hospitalized days and inpatient costs (aPR: 1.4; 95% CI: 1.1–1.7 and aPR: 1.3; 95% CI: 
1.1–1.6, respectively). Being born preterm was also significantly associated with high 
number of hospitalized days and inpatient costs for children with CLP (aPR: 1.9; 95% CI: 
1.2–3.1 and aPR: 2.1; 95% CI: 1.3–3.4, respectively). History of low birth weight was 
significantly associated with a higher number of hospitalized days for children with CLP 
(aPR 2.7; 95% CI: 1.6–4.3), higher inpatient costs for children with CL (aPR 3.0; 95% CI: 
1.1–8.1), and hospitalized days and higher inpatient costs for children with CP (aPR 2.7; 
95% CI: 1.5–4.8; aPR 2.3; 95% CI: 1.3–4.0, respectively). The only consistent association 
with high resource use during both birth and post-birth hospitalizations stratified by OFC 
subtype was the presence of another major birth defect. Children with all subtypes of OFC 
who also had another major birth defect were 3.3–5.9 times more likely to have had a high 
number of hospitalized days and 4.0–11.0 times more likely to have had high inpatient costs 
during the birth hospitalization (Table 4).
Because fewer children had post-birth hospitalizations, the post-birth analyses had less 
power to detect associations, particularly for children with CL (Table 4). Among children 
with CP, those with public insurance were 2.4 times more likely to have had a high number 
of hospitalized days and 3.3 times more likely to have had high inpatient costs than their 
counterparts with private insurance. Also, among children with CP, being born low birth 
weight was associated with higher likelihoods of high hospitalized days and high inpatient 
costs.
Similar to the birth hospitalization results, females with CLP were more likely to have had a 
high number of hospitalized days and inpatient costs than males with CLP during the post-
birth period. Among children with CLP, the presence of other major birth defects was an 
even stronger predictor of high post-birth resource use than for birth hospitalizations. 
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Children with non-isolated OFC were 2.8–9.4 and 3.3–9.7 times more likely to have had a 
high number of hospitalized days and inpatient costs, respectively (Table 4).
The results for the analysis of total hospitalizations from birth to age two were similar to 
those that have been previously described for birth and post-birth hospitalizations (Table 4). 
Females were more likely than males to have high resource use among children with CLP 
and were less likely to have a high number of hospitalized days among children with CP. 
Being born low birth weight was a significant predictor of a high number of total 
hospitalized days for children with CLP and CP and high inpatient costs for children with 
CL and CP. Children with non-isolated OFC were more likely to have a high number of total 
hospitalized days and inpatient costs for all OFC subtypes. When examining factors 
associated with total hospitalizations initiated before age two years, public insurance at the 
birth hospitalization was a predictor of higher number of hospitalized days and costs for 
children with CLP and higher number of hospitalized days for children with CP compared to 
those with private insurance.
DISCUSSION
This study is the largest population-based study of hospital use in children with orofacial 
clefts in the United States and among the few to examine maternal, child, and system 
characteristics associated with high resource use in these children. This report describes high 
hospital resource use for Florida-born children with OFC, stratified by OFC subtype. About 
68% of children had isolated OFC, which is similar to distributions found in several other 
studies (Cassell et al., 2008; Watkins et al., 2014; Weiss et al., 2009). The number of 
hospitalized days and estimated inpatient costs were significantly greater for children with 
non-isolated OFC compared to isolated OFC for all OFC subtypes, which was to be 
expected and similar to other previous findings (Boulet et al., 2009; Cassell et al., 2008; 
Weiss et al., 2009).
This large population-based study can be compared with several studies that examined 
hospital use and costs for children with OFC by cleft subtypes (Basseri et al., 2011; Boulet 
et al., 2009; Cassell et al., 2008; Centers for Disease Control and Prevention, 2007; 
Deleyiannis et al., 2013; Nguyen et al., 2013; Russo and Elixhauser, 2007; Weiss et al., 
2009). Our results were similar to recent studies in that the presence of other major birth 
defects, in addition to OFC, was associated with both higher hospitalization costs (Boulet et 
al., 2009; Cassell et al., 2008; Weiss et al., 2009) and hospitalized days (Weiss et al., 2009). 
Our study is most comparable to that of Weiss et al. (2009) in terms of study design and 
analysis. Although we observed the highest mean costs and hospitalized days for children 
with isolated and non-isolated CP during birth and post-birth hospitalizations, Weiss et al. 
(2009) observed a similar association in children with isolated CP at birth hospitalization 
only. Our findings support those from a more recent study in which researchers concluded 
that compared to children with the other two OFC subtypes, the highest hospital charges and 
payments were reported for children with isolated CP (Deleyiannis et al., 2013). However, 
that study only used one hospital for its study sample and included a small study sample 
(Deleyiannis et al., 2013). In addition, of the two studies that used birth defects registry data 
and examined healthcare use in the first year of life, one concluded that children with CP 
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incurred the highest cost (Boulet et al., 2009), whereas the other found that CLP was 
associated with the highest total cost followed closely by CP (Cassell et al., 2008). The 
differences observed in these two studies may be due to ascertainment definitions, coding 
differences, payer type examined (private vs. public) and study time frame.
Although our study utilized data from a single state, our results are similar to studies that 
utilized national databases, such as the AHRQ HCUP Kids’ Inpatient Database and the 
Nationwide Inpatient Sample (Centers for Disease Control and Prevention, 2007; Russo and 
Elixhauser, 2007). Russo and Elixhauser (2007) also observed a higher number of mean 
hospitalized days and costs for children with CP compared to those with cleft lip with or 
without cleft palate and similar hospitalization costs for both groups; however, a major 
limitation of that study was the lack of information on the presence or absence of other 
major birth defects as well as lack of inclusion of three distinct groups of OFC. A study of 
hospitalized days and charges in children with selected birth defects in the United States also 
found that neonates with CP had a higher number of hospitalized days and costs compared 
to children with cleft lip with or without cleft palate (Centers for Disease Control and 
Prevention, 2007); that study did not distinguish between cleft lip and cleft lip with palate 
and did not stratify by the presence of other major birth defects.
Our study was subject to several limitations, including the use of a passive birth defects 
surveillance system, the FBDR, in which ICD-9-CM codes were used to identify and 
classify children with OFC and other birth defects instead of verbatim or clinically-verified 
diagnoses. We were not able to capture post-birth hospitalizations that occurred out-of-state 
or at a Florida hospital or clinic that does not report to AHCA. While approximately 290 
Florida hospitals report data to the AHCA, not all hospitals are required to report to AHCA, 
such as military hospitals (Florida Agency for Health Care Administration, 2013). 
Therefore, post-birth and total hospitalization costs may be an underestimate of the total 
resource use of the study cohort. Additionally, we did not have a comparison group of 
unaffected children, so we were unable to make comparisons between the hospital resource 
use of Florida-born children with OFC and that of unaffected children. However, the focus 
of this analysis was an internal comparison of costs for children with OFC by subtype and 
isolated versus non-isolated OFC. Furthermore, we did not have information on the prenatal 
experience, including any prenatal diagnosis of OFC or other major birth defects. However, 
only 3% to 33% of OFC are diagnosed prenatally (varies by subtype) (Johnson et al., 2009; 
Robbins et al., 2010); lack of prenatal diagnosis is potentially a limitation because mothers 
of fetuses with a prenatal diagnosis of a birth defect may be referred to, or elect to, deliver in 
a hospital with higher level of neonatal care, thus accruing higher hospitalized days and 
costs. Also, we observed a higher proportion of Hispanic and foreign-born mothers among 
children with non-isolated OFC compared to children with isolated OFC. Because our study 
only included live-born children, this difference could reflect differential access to prenatal 
diagnostics or rates of elective termination between Hispanic and non-Hispanic white 
women, as Hispanic women may be less likely to terminate a pregnancy due to birth defects 
(Jones et al., 2002).
Another limitation of our study was the use of a statewide cost-to-charge ratio to convert 
inpatient charges to costs, which may be problematic due to variability in cost mark-up 
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between hospitals and departments within a hospital (Rogowski et al., 1999). Also, 2001 
cost-to-charge ratios were used to impute the missing cost-to-charge ratios for 1998–2000 
because these ratios were unavailable for years prior to 2001. Thus, costs for hospitalizations 
during 1998–2000 are a slight underestimate given that cost-to-charge ratios have decreased 
over time. Another limitation is that hospital discharge data only include facility fees and 
thus professional fees are excluded. The implication is that hospitalization costs per child 
could be understated by about one-fifth in the present analysis, based on an analysis of 
claims data from California (Rogowski et al., 1998).
An additional limitation was that some birth hospitalization costs may have been applied to 
the mothers’ hospital discharge records. Because we did not have access to maternal 
delivery records, we could not account for any costs on the maternal delivery record related 
to the child. Also, some of our results must be interpreted with caution due to small numbers 
and wide confidence intervals. Lastly, our study only reflects information from one state and 
may not be generalizable to other states and the U.S. population.
Strengths of our study included the use of data from the FBDR, which included multiple 
sources of birth defects ascertainment (Salemi et al., 2010; Salemi et al., 2011; Salemi et al., 
2012). Our study used a combination of statewide, population-based registry data linked to 
longitudinal hospital data. While not actively ascertained, the FBDR’s overall completeness 
of ascertainment of birth defects, including OFC, is high, about 88%, although 
ascertainment varies by specific birth defect (Salemi et al., 2011; Salemi et al., 2012). 
Although our study only included one state, Florida was the fourth most populous state in 
2010, ranked fourth in annual number of live births in the United States and has one of the 
highest rates of in- and out-migration (Martin et al., 2012; Perry, 2003; Schachter, 2004). 
Additionally, in 2010, Florida ranked third in annual live births to Hispanic women and first 
in annual live births to African-American women (Martin et al., 2012). We also were able to 
convert charges to current dollar costs. Finally, we were able to analyze the associations 
between high resource use and a wide variety of maternal, child, and other characteristics by 
OFC subtype, which was another strength of the study.
Finally, our findings can inform planning for hospital resources, treatment, and management 
of OFC. Furthermore, this information may be helpful for guiding clinicians, researchers, 
and public health officials concerned with treatment, management, and service planning for 
children with OFC, including counseling of an OFC prenatal diagnosis. Our study is 
important and fits with studies of other health outcomes for this population because it may 
be likely that the higher users of hospital care during infancy will have higher service use 
throughout their childhood and lifetime.
CONCLUSIONS
We observed longer hospitalizations and higher inpatients costs during the birth 
hospitalization and hospitalizations for the first two years of life for children with non-
isolated OFC compared to children with isolated OFC, with the greatest resource use for 
children with CP. Children with CP had the greatest hospital resource use and the presence 
of other major birth defects was the most important predictor of high resource use, although 
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factors, such as preterm birth and low birth weight, may be predictors of high resource use 
for some subsets of children. This study highlights the use of linking existing birth defects 
surveillance data with hospital discharge data to evaluate the impact of birth defects on the 
healthcare system.
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Figure 1. 
Inclusion flowchart for children with orofacial clefts, born 1998–2006, in the Florida Birth 
Defects Registry and linked with hospital discharge data up toage two years
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Table 2
Distribution of other major birth defects for Florida-born children with non-isolated orofacial clefts, 1998–
2006
Cleft lip with cleft palate
(n=363)
Cleft lip
(n=45)
Cleft palate
(n=266)
Accompanying defecta N (%) N (%) N (%)
Congenital heart defects 230 (63.4) 26 (57.8) 157 (59.0)
Musculoskeletal defects 135 (37.2) 16 (35.6) 163 (61.3)
Chromosomal abnormalities 87 (24.0) 6 (13.3) 59 (22.2)
Genitourinary defects 69 (19.0) 6 (13.3) 60 (22.6)
Congenital lung abnormalities 54 (14.9) 5 (11.1) 33 (12.4)
Eye/Ear defects 48 (13.2) 14 (31.1) 28 (10.5)
Gastrointestinal defects 47 (13.0) NR 48 (18.1)
Central nervous system defects 11 (3.0) NR 8 (3.0)
Notes: Orofacial clefts sub-types are mutually exclusive; Non-isolated= International Classification of Disease, 9th revision; Clinical Modification 
(ICD-9-CM) codes for other major birth defects present in the Florida Birth Defects Registry, including syndromes.
NR: not reported due to cell counts of < 5.
a
Birth defect groups are not mutually exclusive- ICD-9-CM codes used: congenital heart defects (745.00–747.90), musculoskeletal defects 
(754.00–756.90), chromosomal abnormalities (758.00–758.90), genitourinary (752.00 – 753.90), congenital lung abnormalities (748.00-478.90), 
eye/ear defects (743.00–744.90) gastrointestinal (750.00–751.90), central nervous system (740.00 –742.90).
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